153 related articles for article (PubMed ID: 34462871)
1. A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF
Georgiou A; Stewart A; Vlachogiannis G; Pickard L; Valeri N; Cunningham D; Whittaker SR; Banerji U
Cell Oncol (Dordr); 2021 Oct; 44(5):1197-1206. PubMed ID: 34462871
[TBL] [Abstract][Full Text] [Related]
2. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
3. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
4. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
Lindner AU; Carberry S; Monsefi N; Barat A; Salvucci M; O'Byrne R; Zanella ER; Cremona M; Hennessy BT; Bertotti A; Trusolino L; Prehn JHM
Int J Cancer; 2020 Nov; 147(10):2891-2901. PubMed ID: 32700762
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of
Georgiou A; Stewart A; Cunningham D; Banerji U; Whittaker SR
Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
8. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
9. Expanded Low Allele Frequency
Loree JM; Dowers A; Tu D; Jonker DJ; Edelstein DL; Quinn H; Holtrup F; Price T; Zalcberg JR; Moore MJ; Karapetis CS; O'Callaghan CJ; Waring P; Kennecke HF; Hamilton SR; Kopetz S
Clin Cancer Res; 2021 Jan; 27(1):52-59. PubMed ID: 33087330
[TBL] [Abstract][Full Text] [Related]
10. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
11. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E;
Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376
[TBL] [Abstract][Full Text] [Related]
12. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
14. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Moiseyenko VM; Moiseyenko FV; Yanus GA; Kuligina ES; Sokolenko AP; Bizin IV; Kudriavtsev AA; Aleksakhina SN; Volkov NM; Chubenko VA; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Pashkov DV; Ivantsov AO; Venina AR; Sokolova TN; Preobrazhenskaya EV; Mitiushkina NV; Togo AV; Iyevleva AG; Imyanitov EN
Clin Drug Investig; 2018 Jun; 38(6):553-562. PubMed ID: 29470838
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
16. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
17. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.
Baba O; Bidikian A; Mukherji D; Shamseddin A; Temraz S; Fakhruddin N; Khazzouh M; Ghizzawi D; Abdel Khalek R; Zaatari G; Mahfouz R
Gene; 2022 Aug; 834():146646. PubMed ID: 35680020
[TBL] [Abstract][Full Text] [Related]
18. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.
Kim SA; Park H; Kim KJ; Kim JW; Sung JH; Nam M; Lee JH; Jung EH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Lee KW
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2995-3005. PubMed ID: 34853888
[TBL] [Abstract][Full Text] [Related]
20. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
